中国胸心血管外科临床杂志

中国胸心血管外科临床杂志

左心疾病相关性肺动脉高压

查看全文

各种类型的肺动脉高压中,左心疾病相关性肺动脉高压(pulmonary hypertension due to left heart disease,PH-LHD)最为常见。尽管目前有许多针对肺动脉高压的治疗措施,但是肺动脉高压的诊断以及分类尚未明确的情况下盲目的采用治疗措施可能是有害的。因此,在做出治疗决定之前对肺动脉高压的精确诊断和分类是至关重要的。然而,在临床工作中对肺动脉高压诊断的分类依然存在一定的困难。而左心疾病相关性肺动脉高压又往往同时存在毛细血管前性及毛细血管后性肺动脉高压的复杂病理生理机制,临床治疗手段有限,对于临床工作是极大的挑战。在此,本文对左心疾病相关性肺动脉高压的研究现状做一综述。

Pulmonary hypertension due to left heart disease (PH-LHD) is the most common in various types of pulmonary hypertension. Although there are many treatments for pulmonary hypertension, it maybe harmful when we adopt treatment without detrimental diagnosis and classification of pulmonary hypertension. Therefore, it’s very crucial to have accurate diagnosis and classification of pulmonary hypertension before making treatment decisions. However, there are still some difficulties in the classification of pulmonary hypertension in clinical work. It’s a great challenge with limited treatment to solve the PH-LHD which often has complicated pathophysiological mechanisms of precapillary and postcapillary pulmonary hypertension. Here, we review the research status of PH-LHD.

关键词: 肺动脉高压; 诊断; 左心疾病相关性肺动脉高压

Key words: Pulmonary hypertension; diagnosis; pulmonary hypertension due to left heart disease

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Rosenkranz S. Pulmonary hypertension 2015: Current definitions, terminology, and novel treatment options. Clin Res Cardiol, 2015, 104(3): 197-207.
2. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol, 2013, 62(25): D34-D41.
3. Galie`N, Hoeper MM, Humbert M, et al. ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J, 2009, 30(20): 2493-2537.
4. Hansdottir S, Groskreutz DJ, Gehlbach BK. WHO's in second?: A practical review of World Health Organization group 2 pulmonary hypertension. Chest, 2013, 144(2): 638-650.
5. Guazzi M, Borlaug BA. Pulmonary hypertension due to left heart disease. Circulation, 2012, 126(8): 975-990.
6. Hoeper MM, Barberà JA, Channick RN, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol, 2009, 54(1 Suppl): S85-S96.
7. Vachiéry JL, Adir Y, Barberà JA, et al. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol, 2013, 62(25 Suppl): D100-108.
8. Schwartzenberg S, Redfield MM, From AM, et al. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol, 2012, 59(5): 442-451.
9. Borlaug BA, Kane GC, Melenovsky V, et al. Abnormal right ventricular pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur Heart J, 2016, 37(43): 3293-3302.
10. Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation, 2016, 134(1): 73-90.
11. Hassoun PM, Mouthon L, Barberà JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol, 2009, 54(1 Suppl): S10-S19.
12. Opitz CF, Hoeper MM, Gibbs JS, et al. Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol, 2016, 68(4): 368-378.
13. Guha A, Amione-Guerra J, Park MH. Epidemiology of pulmonary hypertension in left heart disease. Prog Cardiovasc Dis, 2016, 59(1): 3-10.
14. McLaughlin VV, Shah SJ, Souza R, et al. Management of pulmonary arterial hypertension. J Am Coll Cardiol, 2015, 65(18): 1976-1997.
15. MacIver DH, Adeniran I, MacIver IR, et al. Physiological mechanisms of pulmonary hypertension. Am Heart J, 2016, 180: 1-11.
16. Opotowsky AR. Clinical evaluation and management of pulmonary hypertension in the adult with congenital heart disease. Circulation, 2015, 131(2): 200-210.
17. Rich JD, Rich S. Clinical diagnosis of pulmonary hypertension. Circulation, 2014, 130(20): 1820-1830.
18. Jamous F. Pulmonary hypertension. Chest, 2014, 145(2): 432-433.
19. Dunlap B, Weyer G. Pulmonary hypertension: diagnosis and treatment. Am Fam Physician, 2016, 94(6): 463-469.
20. Hemnes AR. Pulmonary arterial hypertension treatment guidelines: new answers and even more questions. Chest, 2014, 146(2): 239-241.
21. White RJ. Estrogen: Friend or Foe in pulmonary hypertension? Am J Respir Crit Care Med, 2016, 193(10): 1084-1086.
22. Barnett CF, De Marco T. Treatment of advanced group 2 PH. Prog Cardiovasc Dis, 2016, 59(1): 78-86.
23. Preston IR. Properly diagnosing pulmonary arterial hypertension. Am J Cardiol, 2013, 111(8 Suppl): 2C-9C.
24. Naeije R, D'Alto M. The Diagnostic challenge of group 2 pulmonary hypertension. Prog Cardiovasc Dis, 2016, 59(1): 22-29.
25. Muneuchi J, Nagatomo Y, Watanabe M, et al. Relationship between pulmonary arterial resistance and compliance among patients with pulmonary arterial hypertension and congenital heart disease. J Thorac Cardiovasc Surg, 2016, 152(2): 507-513.
26. Reddy S, Bernstein D. Molecular mechanisms of right ventricular failure. Circulation, 2015, 132(18): 1734-1742.
27. Lala A, Pinney SP. Recognizing pulmonary hypertension and right ventricular dysfunction in heart failure. Prog Cardiovasc Dis, 2016, 58(4): 416-424.
28. Gerges C, Gerges M, Skoro-Sajer N, Hemodynamic Thresholds for Pre-capillary Pulmonary Hypertension. Hemodynamic Thresholds for Pre-capillary Pulmonary Hypertension. Chest, 2016, 149(4): 1061-1073.
29. Gargani L, Pignone A, Agoston G, et al. Clinical and echocardiographic correlations of exercise-induced pulmonary hypertension in systemic sclerosis: a multicenter study. Am Heart J, 2013, 165(2): 200-207.
30. Vanderpool RR, Naeije R. Progress in pulmonary hypertension with left heart failure. beyond new definitions and acronyms. Am J Respir Crit Care Med, 2015, 192(10): 1152-1154.
31. Burger IA, Husmann L, Herzog BA, et al. Main pulmonary artery diameter from attenuation correction CT scans in cardiac SPECT accurately predicts pulmonary hypertension. J Nucl Cardiol, 2011, 18(4): 634-641.
32. Wilcox SR, Kabrhel C, Channick RN. Pulmonary Hypertension and Right Ventricular Failure in Emergency Medicine. Ann Emerg Med, 2015, 66(6): 619-628.
33. Schermuly RT, Ghofrani HA, Wilkins MR, et al. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol, 2011, 8(8): 443-455.
34. Tsukashita M, Takayama H, Takeda K, et al. Effect of pulmonary vascular resistance before left ventricular assist device implantation on short- and long-term post-transplant survival. J Thorac Cardiovasc Surg, 2015, 150(5): 1352-1360.
35. Sciancalepore MA, Maffessanti F, Patel AR, et al. Three-dimensional analysis of interventricular septal curvature from cardiac magnetic resonance images for the evaluation of patients with pulmonary hypertension. Int J Cardiovasc Imaging, 2012, 28(5): 1073-1085.
36. Proietti M, Marra AM, Tassone EJ, et al. Frequency of left ventricular hypertrophy in non-valvular atrial fibrillation. Am J Cardiol, 2015, 116(6): 877-882.
37. Hernández-Rivera H, Martínez-González H, Casal J, et al. Pulmonary arterial hypertension: from pathophysiology to management. Bol Asoc Med P R, 2011, 103(1): 34-40.
38. Murray F, Maclean MR, Insel PA. Role of phosphodiesterases in adult-onset pulmonary arterial hypertension. Handb Exp Pharmacol, 2011, (204): 279-305.
39. Chemla D, Humbert M, Sitbon O, et al. Systolic and mean pulmonary artery pressures: are they interchangeable in patients with pulmonary hypertension? Chest, 2015, 147(4): 943-950.
40. Kammerlander AA, Marzluf BA, Graf A, et al. Right ventricular dysfunction, but not tricuspid regurgitation, is associated with outcome late after left heart valve procedure. J Am Coll Cardiol, 2014, 64(24): 2633-2642.
41. Zhou X, Wang D, Castro CY, et al. A pulmonary hypertension model induced by continuous pulmonary air embolization. J Surg Res, 2011, 170(1): e11-e16.
42. Tan Q, Kerestes H, Percy MJ, et al. Erythrocytosis and pulmonary hypertension in a mouse model of human HIF2A gain of function mutation. J Biol Chem, 2013, 288(24): 17134-17144.
43. Lakshminrusimha S, Konduri GG, Steinhorn RH. Considerations in the management of hypoxemic respiratory failure and persistent pulmonary hypertension in term and late preterm neonates. J Perinatol, 2016, 36(Suppl 2): S12-S19.
44. Guazzi M, Phillips SA, Arena R, et al. Endothelial dysfunction and lung capillary injury in cardiovascular diseases. Prog Cardiovasc Dis, 2015, 57(5): 454-462.
45. Azarbar S, Dupuis J. Lung capillary injury and repair in left heart disease: a new target for therapy? Clin Sci (Lond), 2014, 127(2): 65-76.
46. Voelkel NF, Cool C, Taraceviene-Stewart L, et al. Janus face of vascular endothelial growth factor: the obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension. Crit Care Med, 2002, 30(5 Suppl): S251-S256.
47. White HA, Jin Y, Chicoine LG, et al. Hypoxic proliferation requires EGFR-mediated ERK activation in human pulmonary microvascular endothelial cells. Am J Physiol Lung Cell Mol Physiol, 2017, 312(5): L649-L656.
48. Ptaszyńska-Kopczyńska K, Krentowska A, Sawicka E, et al. The strengths and weaknesses of non-invasive parameters obtained by echocardiography and cardiopulmonary exercise testing in comparison with the hemodynamic assessment by the right heart catheterization in patients with pulmonary hypertension. Adv Med Sci, 2016, 62(1): 39-44.
49. Zimmer A, Teixeira RB, Bonetto JH, S, et al. Effects of aerobic exercise training on metabolism of nitric oxide and endothelin-1 in lung parenchyma of rats with pulmonary arterial hypertension. Mol Cell Biochem, 2017, 429(1-2): 73-89.
50. Li T, Chen Y, Zang W, et al. Prostacyclin and its analogues in pulmonary artery hypertension: a meta-analysis. Curr Med Res Opin, 2013, 29(8): 889-899.
51. Yeager ME, Nguyen CM, Belchenko DD, et al. Circulating fibrocytes are increased in children and young adults with pulmonary hypertension. Eur Respir J, 2012, 39(1): 104-111.
52. Lancellotti P, Magne J, Dulgheru R, et al. Clinical significance of exercise pulmonary hypertension in secondary mitral regurgitation. Am J Cardiol, 2015, 115(10): 1454-1461.
53. del Cerro Marín MJ, Sabaté Rotés A, Rodriguez Ogando A, et al. Assessing pulmonary hypertensive vascular disease in childhood. Data from the Spanish registry. Am J Respir Crit Care Med, 2014, 190(12): 1421-1429.
54. Arai S, Kurasawa K, Maezawa R, et al. Systemic sclerosis complicated by arrhythmogenic right ventricular dysplasia that was misinterpreted as pulmonary arterial hypertension. Mod Rheumatol, 2012, 22(1): 152-157.
55. Umar S, Iorga A, Matori H, et al. Estrogen rescues preexisting severe pulmonary hypertension in rats. Am J Respir Crit Care Med, 2011, 184(6): 715-723.
56. Naeije R, D'Alto M, Forfia PR. Clinical and research measurement techniques of the pulmonary circulation: the present and the future. Prog Cardiovasc Dis, 2015, 57(5): 463-472.
57. Maemura S, Ishizuka M, Nakata R, et al. Pulmonary hypertension caused by persistent anomalous vertical vein bridging the left subclavian vein and left atrium with hypertrophic cardiomyopathy. Circulation, 2014, 130(18): e153-e156.
58. Guazzi M, Vicenzi M, Arena R, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation, 2011, 124(2): 164-174.
59. Mohammed SF, Hussain I, AbouEzzeddine OF, et al. Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation, 2014, 130(25): 2310-2320.
60. Rich S. Future of clinical trials for pulmonary hypertension. Circulation, 2011, 123(25): 2919-2921.
61. Yeo KK, Maddox TM, Carey E, et al. Right- and left-sided heart catheterization as a quality marker for catheterization laboratories (from the national Veterans Affairs clinical assessment reporting and tracking program). Am J Cardiol, 2014, 114(11): 1758-1762.
62. Song MY, Makino A, Yuan JX. STIM2 contributes to enhanced store-operated ca entry in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Pulm Circ, 2011, 1(1): 84-94.
63. Forfia PR, Vachiéry JL. Echocardiography in pulmonary arterial hypertension. Am J Cardiol, 2012, 110(6 Suppl): 16S-24S.
64. Wen L, Sun ML, An P, et al. Frequency of supraventricular arrhythmias in patients with idiopathic pulmonary arterial hypertension. Am J Cardiol, 2014, 114(9): 1420-1425.
65. Quintana E, Suri RM, Thalji NM, et al. Left ventricular dysfunction after mitral valve repair--the fallacy of "normal" preoperative myocardial function. J Thorac Cardiovasc Surg, 2014, 148(6): 2752-2760.
66. Smith BC, Dobson G, Dawson D, et al. Three-dimensional speckle tracking of the right ventricle: toward optimal quantification of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol, 2014, 64(1): 41-51.
67. Hinrichs JB, Werncke T, Kaireit T, et al. C-Arm computed tomography adds diagnostic information in patients with chronic thromboembolic pulmonary hypertension and a positive V/Q SPECT. Rofo, 2017, 189(1): 49-56.
68. Mishra A, Kumar B, Dutta V, et al. Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. J Cardiothorac Vasc Anesth, 2016, 30(3): 639-646.
69. Gin-Sing W. Pulmonary arterial hypertension: a multidisciplinary approach to care. Nurs Stand, 2010, 24(38): 40-47.
70. Meyer M. Left ventricular atrophy in pulmonary arterial hypertension: a sinister dexter conundrum. J Am Coll Cardiol, 2014, 64(1): 38-40.
71. Lange SA, Braun MU, Schoen SP, et al. Latent pulmonary hypertension in atrial septal defect: Dynamic stress echocardiography reveals unapparent pulmonary hypertension and confirms rapid normalisation after ASD closure. Neth Heart J, 2013, 21(7-8): 333-343.
72. Lee SH, Kwon BS, Kim GB, et al. Prophylactic pulmonary artery reduction in a young female with severe pulmonary hypertension from complete atrioventricular septal defect. Korean Circ J, 2017, 47(1): 136-140.
73. Manders E, Bogaard HJ, Handoko ML, et al. Contractile dysfunction of left ventricular cardiomyocytes in patients with pulmonary arterial hypertension. J Am Coll Cardiol, 2014, 64(1): 28-37.
74. Yalonetsky S, Eden H, Lessick J, et al. Impact of functional mitral regurgitation on right ventricular function and outcome in patients with right ventricular infarction. Am J Cardiol, 2014, 114(1): 36-41.
75. Gomberg-Maitland M, Bull TM, Saggar R, et al. New trial designs and potential therapies for pulmonary artery hypertension. J Am Coll Cardiol, 2013, 62(25 Suppl): D82-91.
76. Wilson SR, Ghio S, Scelsi L, et al. Pulmonary hypertension and right ventricular dysfunction in left heart disease (group 2 pulmonary hypertension). Prog Cardiovasc Dis, 2012, 55(2): 104-118.
77. Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol, 2013, 62(25 Suppl): D42-50.
78. Tuder RM, Archer SL, Dorfmüller P, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol, 2013, 62(25 Suppl): D4-12.
79. Vonk-Noordegraaf A, Haddad F, Chin KM, et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol, 2013, 62(25 Suppl): D22-33.
80. Wan SH, Vogel MW, Chen HH. Pre-clinical diastolic dysfunction. J Am Coll Cardiol, 2014, 63(5): 407-416.
81. Hemnes AR, Brittain EL, Trammell AW, et al. Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med, 2014, 189(3): s325-334.
82. Apitz C, Hansmann G, Schranz D. Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart, 2016, 102(Suppl 2): ii23-ii29.
83. Varghese R, Itagaki S, Anyanwu AC, et al. Predicting early left ventricular dysfunction after mitral valve reconstruction: the effect of atrial fibrillation and pulmonary hypertension. J Thorac Cardiovasc Surg, 2014, 148(2): 422-427.
84. Fritz JS, Smith KA. The Pulmonary Hypertension Consult: Clinical and Coding Considerations. Chest, 2016, 150(3): 705-713.
85. Latus H, Apitz C, Schmidt D, Jux C, et al. Potts shunt and atrial septostomy in pulmonary hypertension caused by left ventricular disease. Ann Thorac Surg, 2013, 96(1): 317-319.
86. Levitov A, Frankel HL, Blaivas M, et al. Guidelines for the appropriate use of bedside general and cardiac ultrasonography in the evaluation of critically Ill patients-part II: cardiac ultrasonography. Crit Care Med, 2016, 44(6): 1206-1227.
87. Howard JL, Acker MA, Woo YJ. Predicting right ventricular failure in the modern, continuous flow left ventricular assist device era. Ann Thorac Surg, 2013, 96(3): 857-863.
88. Santarém OL, Cleva Rd, Sasaya FM, et al. Left ventricular dilation and pulmonary vasodilatation after surgical shunt for treatment of pre-sinusoidal portal hypertension. PLoS One, 2016, 11(4): e0154011.
89. Cosa N, Costa E Jr. Inhaled pulmonary vasodilators for persistent pulmonary hypertension of the newborn: safety issues relating to drug administration and delivery devices. Med Devices (Auckl), 2016, 9: 45-51.
90. Rubin LJ. Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT. Circulation, 2013, 128(5): 475-476.
91. Piao C, Zhu Y, Zhang C, et al. Identification of multiple ACVRL1 mutations in patients with pulmonary arterial hypertension by targeted exome capture. Clin Sci (Lond), 2016, 130(17): 1559-1569.
92. Dumas de la Roque E, Quignard JF, Ducret T, et al. Beneficial effect of dehydroepiandrosterone on pulmonary hypertension in a rodent model of pulmonary hypertension in infants. Pediatr Res, 2013, 74(2): 163-169.
93. Weinberg A, Mongero L, Armstrong B. ECMO cannulation strategy for pulmonary hypertension: an alternative approach to traditional Veno-Arterial ECMO. Perfusion, 2016, 31(7): 614-617.
94. Kreitner KF. Noninvasive imaging of pulmonary hypertension. Semin Respir Crit Care Med, 2014, 35(1): 99-111.
95. Danilowicz-Szymanowicz L, Lewicka E, Dabrowska-Kugacka A, et al. Microvolt T-wave alternans profiles in patients with pulmonary arterial hypertension compared to patients with left ventricular systolic dysfunction and a group of healthy volunteers. Anatol J Cardiol, 2016, 16(11): 825-830.
96. Pang L, Qi J, Gao Y, et al. Adrenomedullin alleviates pulmonary artery collagen accumulation in rats with pulmonary hypertension induced by high blood flow. Peptides, 2014, 54: 101-107.
97. de Perrot M. Operability assessment in chronic thromboembolic pulmonary hypertension (CTEPH): Don't miss the chance of a second opinion! J Thorac Cardiovasc Surg, 2016, 152(3): 656-657.
98. Qian C, Xihong G, Jing Y, et al. The assessment of right ventricular function in patients with pulmonary arterial hypertension with cardiac magnetic resonance imaging: a meta-analysis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, 2015, 27(12): 998-1001.
99. Sztrymf B, Günther S, Artaud-Macari E, et al. Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension. Chest, 2013, 144(5): 1512-1520.
100. Shah SJ. Pulmonary hypertension. JAMA, 2012, 308(13): 1366-1374.
101. Eleid MF, Nishimura RA, Sorajja P, et al. Systemic hypertension in low-gradient severe aortic stenosis with preserved ejection fraction. Circulation, 2013, 128(12): 1349-1353.